Skip to main content
. Author manuscript; available in PMC: 2014 Jun 30.
Published in final edited form as: Nat Biotechnol. 2011 Dec 18;30(1):78–82. doi: 10.1038/nbt.2065

Figure 2. SNV detection and intersection.

Figure 2

(a) SNVs detected from the PBMC and saliva samples in each platform were combined. The unions of SNVs in each platform were then intersected. Sensitivity was measured against the Illumina Omni array. Ti/Tv is the transition-to-transversion ratio. The known and novel counts were based on dbSNP. ‘Sanger’ and ‘validated’ represent validation by Sanger sequencing and Illumina sequencing (with Agilent target enrichment capture), respectively. (b) Comparing platform-specific SNVs to non-SNV calls in another platform. IL, Illumina; CG, Complete Genomics.